Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acetaminophen products do not need aspirin cross-reactivity warning, McNeil argues.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN-SENSITIVE WARNING ON ACETAMINOPHEN UNJUSTIFIED, McNEIL ARGUES in a May 15 response to a Whitehall-Robins Health- care submission to FDA proposing an aspirin cross-reactivity label warning be required on acetaminophen products. The marketer of Tylenol acetaminophen argues that after a review of the scientific data and evidence from the product's four-decade marketing history, "there is no substantial or credible scientific evidence that cross-reactivity between aspirin and acetaminophen occurs at any clinically important level." The firm concludes "there is no justification for an aspirin-sensitive cross-reactivity warning on acetaminophen products."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel